Respiratory

THE U.S. Food and Drug Administration has approved a novel inhaled formulation of treprostinil for adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), adding a new option for improving exercise ability in these patient populations.

In a Phase III clinical trial, nerandomilast, an oral phosphodiesterase 4B inhibitor, was associated with a smaller decline in lung function over 52 weeks in patients with progressive pulmonary fibrosis, when compared with placebo.

GLP-1 receptor agonists (GLP-1 RAs), widely recognized for their role in metabolic disorders, may offer added support for smokers attempting to quit, according to findings presented at the 2025 American Psychiatric Association Annual Meeting.

Commonly used ICU delirium screening tools often misclassify Spanish-speaking patients according to new research presented at 2025 American Thoracic Society International (ATS) Conference in San Francisco.

Preschool asthma remains one of the most frequently encountered and challenging conditions in pediatric medicine and a new study explores the growing list of controversies surrounding its management.

Critical care nurses may find relief from burnout when a professional therapist is embedded directly within their hospital teams, according to new findings shared at this year’s American Thoracic Society (ATS) International Conference in San Francisco.

At ATS 2025, San Francisco, California, USA, new research reveals that rising temperatures driven by climate change significantly intensify the severity of obstructive sleep apnea (OSA), a condition already underdiagnosed and undertreated.

Clinical trial results for a wearable pulse oximeter and software platform designed to monitor obstructive sleep apnea (OSA) treatment response were presented at the American Thoracic Society (ATS) 2025 International Conference in San Francisco.